Galmed Pharma Reports Q1 2024 Financials

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals Ltd. reported a condensed consolidated financial overview for the first quarter ending March 31, 2024, highlighting a net loss of $1,275 thousand, a decrease in total assets from $16,629 thousand to $14,521 thousand, and a slight comprehensive loss. The report also indicates a reduction in both research and development, as well as general and administrative expenses compared to the previous year.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.